Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Post by HuntNGatheron Sep 28, 2010 4:54pm
552 Views
Post# 17503492

The Pendulum Has to Swing Back

The Pendulum Has to Swing BackI am very hopeful that the impending announcement that TBI Open Label Trial is underway and recruiting patients, I can only imagine that the stock price will get a little shot in the arm.  Remember, there haven't been any deaths resulting from this protocol and significant improvement with Stroke+Occupational Therapy.

The TBI people will be getting their Occupational Therapy in great amounts and we  know that Regenesis provides good results in the 120 day time frame so it is only a matter of time before that becomes a news story.

No offense to the Indian researchers, per se, but this open label will also have the added advantage of being able to show us what a domestic study will run like without the negative assumptions of methodological hanky-panky in the Indian centers.  It will also have more implied rigor to the research.

I would expect that this will precede the FDA meeting to serve a few purposes
1) generate renewed interest after this painfully dull period
2) create a springboard for the FDA news release to bounce on
3) create a net in case the FDA conclusion is not positive. (highly unlikely but still possible).

HnGrowing Bored
Bullboard Posts